Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
Authors
Keywords
-
Journal
BMC Medicine
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-03-05
DOI
10.1186/s12916-015-0280-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer
- (2017) Josh Lauring et al. Journal of the National Comprehensive Cancer Network
- Abstract S6-04: Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II ‘FIRST’ study
- (2015) John FR Robertson et al. CANCER RESEARCH
- Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results
- (2015) Ian Krop et al. CANCER RESEARCH
- A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2− advanced breast cancer
- (2015) Guy Jerusalem et al. CANCER TREATMENT REVIEWS
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer
- (2014) I. Treilleux et al. ANNALS OF ONCOLOGY
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†
- (2014) F. Cardoso et al. ANNALS OF ONCOLOGY
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer
- (2014) F. Rothé et al. ANNALS OF ONCOLOGY
- Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow
- (2014) Glenn Deng et al. BMC CANCER
- Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer
- (2014) L. M. Arthur et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
- (2014) Eva Maria Ciruelos Gil CANCER TREATMENT REVIEWS
- PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
- (2014) A. Markou et al. CLINICAL CANCER RESEARCH
- Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer
- (2014) J. A. Beaver et al. CLINICAL CANCER RESEARCH
- Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy
- (2014) Ilenia Migliaccio et al. CURRENT OPINION IN ONCOLOGY
- Molecular profiling of single circulating tumor cells with diagnostic intention
- (2014) B. Polzer et al. EMBO Molecular Medicine
- Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
- (2014) Felipe Ades et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study
- (2014) Vicky S. Sabine et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAActivating Mutations: A Discordant Role in Early Versus Advanced Hormone-Dependent Estrogen Receptor–Positive Breast Cancer?
- (2014) Ingrid A. Mayer et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients
- (2014) Marta Pestrin et al. Molecular Oncology
- Molecular tests as prognostic factors in breast cancer
- (2014) Marc J. van de Vijver VIRCHOWS ARCHIV
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
- (2013) A. D. Leo et al. JNCI-Journal of the National Cancer Institute
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
- (2013) Stephen RD Johnston et al. LANCET ONCOLOGY
- PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
- (2013) Sherene Loi et al. PLoS One
- Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study
- (2012) John F. R. Robertson et al. BREAST CANCER RESEARCH AND TREATMENT
- FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Polyendocrine Treatment in Estrogen Receptor–Positive Breast Cancer: A “FACT” Yet to Be Proven
- (2012) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Erratum: Integrated genomic analyses of ovarian carcinoma
- (2012) The Cancer Genome Atlas Research Network NATURE
- Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
- (2012) Rita S. Mehta et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
- (2010) Ruth E. Board et al. BREAST CANCER RESEARCH AND TREATMENT
- PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer
- (2010) J. Dupont Jensen et al. CLINICAL CANCER RESEARCH
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
- (2010) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
- (2010) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
- (2009) Matthew J. Ellis et al. BREAST CANCER RESEARCH AND TREATMENT
- Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
- (2009) John F.R. Robertson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
- (2008) Robert J. Paridaens et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now